Novartis AG stock (CH0012005267): new MS drug filing and Q1 momentum attract attention

Novartis AG has filed a key multiple sclerosis drug for EU approval and reported solid Q1 2026 results, keeping the Swiss pharma group in focus for US investors watching global healthcare leaders.

Novartis AG shares remain in focus after the Swiss pharmaceutical group submitted its experimental multiple sclerosis therapy remibrutinib for marketing authorization in the European Union and highlighted solid first-quarter 2026 results, underscoring its pivot toward higher-growth innovative medicines, according to a company update published in May 2026 by Novartis media releases as of 05/2026 and recent quarterly materials on the investor portal from Novartis investors as of 04/2026.

As of: 27.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Novartis
• Sector/industry: Pharmaceuticals and biotechnology
• Headquarters/country: Switzerland
• Core markets: Global prescription medicines, including the US and Europe
• Key revenue drivers: Innovative branded drugs in oncology, immunology, cardiovascular and neuroscience
• Home exchange/listing venue: SIX Swiss Exchange (ticker: NOVN), and American Depositary Receipts on NYSE (ticker: NVS)
• Trading currency: Swiss franc on SIX, US dollar for ADRs

Novartis AG: core business model

Novartis focuses on discovering, developing and commercializing prescription medicines across several therapeutic areas, with an emphasis on innovative, patent-protected drugs rather than generics, according to its corporate profile on Novartis about as of 2025 and strategy materials shared on the investor site by Novartis company overview as of 2025.

The group has reoriented itself in recent years around a more focused portfolio by spinning off its generic drugs unit Sandoz in 2023 and concentrating capital on higher-margin innovative medicines, according to strategic updates from Novartis media releases as of 10/2023 and follow-up investor communications on Novartis financial data as of 2024.

Management describes the strategy as building a "pure-play" innovative medicines company focused on five priority therapeutic areas, with a goal of achieving mid- to high-single-digit sales growth over the medium term and improving core operating margins, according to presentations on the capital markets day referenced by Novartis capital markets day as of 2024 and long-term guidance slides on Novartis earnings events as of 2025.

Novartis generates most of its revenue from patented prescription drugs sold through hospital, specialist and primary-care channels, emphasizing complex therapies that often require significant clinical evidence and regulatory engagement, according to the company’s annual report 2024, which was made available in early 2025 on Novartis annual report 2024 as of 02/2025.

Main revenue and product drivers for Novartis AG

The company’s key growth engines currently include heart-failure treatment Entresto, psoriasis and psoriatic arthritis drug Cosentyx, as well as oncology therapies such as Kisqali for breast cancer and radioligand therapy Pluvicto for metastatic prostate cancer, according to segment breakdowns in the 2024 annual report published in February 2025 by Novartis annual report 2024 as of 02/2025 and commentary in the Q1 2026 slide deck from Novartis Q1 2026 results as of 04/2026.

In its first-quarter 2026 earnings report, Novartis reported that group net sales grew in the mid-single-digit percentage range year over year, driven by double-digit expansion of key brands such as Kisqali and Pluvicto, while older products facing generic competition declined, according to management remarks and summary figures disclosed in April 2026 on Novartis media releases as of 04/2026 and detailed tables in the quarterly report on Novartis quarterly results as of 04/2026.

Management highlighted oncology as one of the strongest segments in the quarter, with radioligand therapies contributing a larger portion of sales as Pluvicto uptake in metastatic castration-resistant prostate cancer expanded in major markets including the US, according to segment commentary in the Q1 2026 presentation furnished on Novartis Q1 2026 presentation as of 04/2026 and accompanying management discussion in the earnings call transcript from Novartis conference call as of 04/2026.

Beyond oncology, immunology and neuroscience are emerging as important growth drivers, with Cosentyx continuing to perform in chronic inflammatory diseases and the company prioritizing late-stage assets such as remibrutinib in multiple sclerosis, according to pipeline overview materials updated in May 2026 on Novartis pipeline as of 05/2026 and therapeutic area summaries provided to investors by Novartis pipeline and R&D as of 2025.

A notable recent development has been the filing of remibrutinib, an oral Bruton’s tyrosine kinase inhibitor, for approval in relapsing multiple sclerosis with the European Medicines Agency, which Novartis disclosed in a May 2026 press release and positioned as a potential pillar of its neuroscience portfolio, according to the announcement on Novartis media releases as of 05/2026 and a related R&D pipeline update on Novartis R&D spotlight as of 05/2026.

From a financial perspective, Novartis reported that core operating income increased faster than sales in Q1 2026, supported by higher volumes of newer products and ongoing cost control, with management reaffirming its full-year 2026 guidance for group net sales to grow in the mid-single-digit percentage range and for core operating income to grow at a higher rate, according to earnings guidance commentary released in April 2026 on Novartis guidance update as of 04/2026 and the outlook section of the quarterly report on Novartis Q1 2026 report as of 04/2026.

For US investors following large-cap healthcare, the American Depositary Receipts of Novartis trade in New York and offer exposure to a diversified portfolio of specialty drugs across oncology, cardiology and neurology, which are areas of sustained demand in the US healthcare system, according to listings data from the New York Stock Exchange cited by NYSE NVS overview as of 05/2026 and summary sector commentary from Novartis ADR program as of 2025.

Conclusion

Novartis AG is positioning itself as a more focused innovative medicines company following the Sandoz spin-off, with recent Q1 2026 results and the EU filing of remibrutinib underlining its emphasis on specialty therapies and late-stage pipeline assets, based on disclosures from April and May 2026 on the company’s media and investor pages via Novartis news as of 05/2026 and earnings documentation on Novartis investors as of 04/2026. For US investors, the New York–traded ADRs provide exposure to a broad pipeline and established blockbusters in global markets, while also embedding typical sector risks such as patent expiries, regulatory scrutiny, clinical trial outcomes and pricing debates in key geographies.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.